| Literature DB >> 35566557 |
Oana-Maria Rosu1,2, Nicoleta Gimiga2,3, Gabriela Stefanescu3,4, Carmen Anton3,4, Gabriela Paduraru2,3, Elena Tataranu5, Gheorghe G Balan3,4, Smaranda Diaconescu6.
Abstract
BACKGROUND AND OBJECTIVES: The aim of this study was to investigate the association between H. pylori positivity with specific symptoms, risk factors and endoscopic patterns among the pediatric population in northeastern Romania.Entities:
Keywords: Helicobacter pylori; children; endoscopic; treatment compliance
Year: 2022 PMID: 35566557 PMCID: PMC9099726 DOI: 10.3390/jcm11092432
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Study population characteristics.
| Study Population | ||||
|---|---|---|---|---|
| Total number | 185 (100%) | 116 (62.7%) | 69 (37.3%) | |
| Age range (years) | 6–17 years | 6–17 years | 6–17 years | 0.79 |
| Mean ± SD | M = 13.12; SD = 3.27 | M = 13.10, SD = 3.33 | M = 13.15, SD = 3.19 | |
| Age groups years, n (%) | ||||
| 6–9 | 32 (17.29%) | 21 (18.1%) | 11 (15.9%) | 0.74 |
| 10–14 | 71 (38.39%) | 41 (35.3%) | 30 (43.5%) | 0.17 |
| 15–17 | 82 (44.32%) | 54 (46.6%) | 28 (40.6%) | 0.85 |
| Sex, n (%) | <0.001 | |||
| Female | 126 (68.10%) | 76 (65.5%) | 50 (72.5%) | 0.02 |
| Male | 59 (31.90%) | 40 (34.5%) | 19 (27.5%) | 0.09 |
| Place of residence, n (%) | <0.001 | |||
| Urban | 69 (37.30%) | 39 (33.6%) | 30 (43.5%) | 0.33 |
| Rural | 116 (62.70%) | 77 (66.4%) | 39 (56.5%) | 0.001 |
| Breastfeeding | <0.001 | |||
| >6 months | 71 (38.38%) | 67 (57.8%) | 47 (68.1%) | 0.07 |
| <6 months | 114 (61.62%) | 49 (42.2%) | 22 (31.9%) | 0.02 |
* Between H. pylori-positive and H. pylori-negative groups.
Figure 1Age distribution of H. pylori-positive children.
Risk factors associated with H. pylori infection.
| Study Population | ||||
|---|---|---|---|---|
| Persons living in a home | <0.001 | |||
| 1 pers/room | 51 (27.6%) | 26 (22.4%) | 25 (36.2%) | 1.00 |
| 2 pers/room | 108 (58.4%) | 73 (62.9%) | 35 (50.7%) | <0.001 |
| >3 pers/room | 26 (14.1%) | 17 (14.7%) | 9 (13%) | 0.16 |
| Type of drinking water | 0.30 | |||
| Bottled water | 55 (29.7%) | 33 (28.4%) | 22 (31.9%) | 0.17 |
| Sink water | 50 (27.0%) | 28 (24.1%) | 22 (31.9%) | 0.48 |
| Fountain water | 80 (43.2%) | 55 (47.4%) | 25 (36.2%) | 0.001 |
| Pets | 0.18 | |||
| Cat | 20 (10.8%) | 14 (12.1%) | 6 (8.7%) | 0.11 |
| Dog | 15 (8.1%) | 11 (9.5%) | 4 (5.8%) | 0.11 |
| Other | 5 (2.7%) | 5 (4.3%) | 0 (0%) | 0.06 |
| None | 145 (78.4%) | 86 (74.1%) | 59 (85.5%) | 0.03 |
| Respiratory infection | 0.57 | |||
| 1–2/year | 141 (76.2%) | 90 (77.5%) | 51 (73.9%) | <0.001 |
| 3–4/year | 44 (23.8%) | 26 (22.4%) | 18 (26.1%) | 0.29 |
| >5/year | 0 (0%) | 0 (0%) | 0 (0%) | - |
| History of antibiotic therapy | 0.34 | |||
| CLR | 67 (36.2%) | 38 (32.7%) | 29 (42.0%) | 0.32 |
| AMX | 1 (0.5%) | 0 (0%) | 1 (1.45%) | - |
| AMC | 14 (7.6%) | 8 (6.9%) | 6 (8.7%) | - |
| Other | 2 (1.08%) | 2 (1.72%) | 0 (0%) | 0.50 |
| Can’t remember | 12 (6.5%) | 7 (6.03%) | 5 (7.2%) | 0.77 |
| CLR + AMX | 5 (2.7%) | 2 (1.72%) | 3 (4.3%) | 0.50 |
| CLR + AMC | 67 (36.2%) | 48 (41.3%) | 19 (27.5%) | 0.001 |
| CLR + MTZ | 2 (1.1%) | 2 (1.7%) | 0 (0%) | 0.50 |
| CLR + OTHER | 2 (1.1%) | 2 (1.7%) | 0 (0%) | 0.50 |
| AMC + OTHER | 1 (0.5%) | 1 (0.9%) | 0 (0%) | - |
| CLR + AMX + AMC | 3 (1.62%) | 2 (1.72%) | 1 (1.4%) | 1.00 |
| CLR + AMX + OTHER | 8 (4.3%) | 3 (2.6%) | 5 (7.2%) | 0.72 |
| CLR + AMX + AMC + MTZ | 1 (0.5%) | 1 (0.9%) | 0 (0%) | - |
| Familial history of upper digestive pathology | 0.32 | |||
| Yes | 31 (16.8%) | 17 (14.7%) | 14 (20.3%) | 0.72 |
| No | 154 (83.2%) | 99 (85.3%) | 55 (79.7%) | <0.001 |
AMX: amoxicillin; AMC: amoxicillin and clavulanic acid; CLR: clarithromycin; MTZ: metronidazole. * Between H. pylori-positive and H. pylori-negative groups.
Clinical presentation symptoms and endoscopic patterns.
| Study Population | ||||
|---|---|---|---|---|
| Clinic | ||||
| Epigastric pain | 105 (56.8%) | 66 (56.9%) | 39 (56.5%) | 0.008 |
| Epigastric + recurrent abdominal pain | 3 (1.6%) | 2 (1.7%) | 1 (1.4%) | 0.56 |
| Epigastric pain + vomiting | 10 (5.4%) | 16 (13.8%) | 8 (11.6%) | 0.10 |
| Recurrent abdominal pain | 27 (14.6%) | 18 (15.5%) | 9 (13.0%) | 0.08 |
| Recurrent abdominal pain + vomiting | 24 (12.9%) | 3 (2.6%) | 7 (10.1%) | 0.20 |
| Vomiting | 3 (1.6%) | 2 (1.7%) | 1 (1.4%) | 0.56 |
| Refractory anemia | 4 (2.2%) | 4 (3.4%) | 0 (0%) | - |
| Other symptoms | 9 (4.9%) | 5 (4.3%) | 4 (5.8%) | 0.73 |
| Endoscopic pattern | <0.001 | |||
| Nodular | 38 (20.5%) | 26 (22.4%) | 12 (17.4%) | 0.02 |
| Nodular + hyperemic | 36 (19.4%) | 36 (31.0%) | - | |
| Nodular + hyperemic + snakeskin | 2 (1.1%) | 1 (0.9%) | 1 (1.4%) | 1.00 |
| Nodular + erosive | 1 (0.5%) | 1 (0.9%) | 0 (0%) | - |
| Nodular + snakeskin | 1 (0.5%) | 0 (0%) | 1 (1.4%) | - |
| Erosive | 6 (3.2%) | 3 (2.6%) | 3 (4.3%) | - |
| Hyperemic | 70 (37.8%) | 25 (21.6%) | 45 (65.2%) | 1.00 |
| Erosive + hyperemic | 1 (0.5%) | 0 (0%) | 1 (1.4%) | 0.01 |
| Hyperemic + snakeskin | 4 (2.1%) | 2 (1,72%) | 2 (2.9%) | 1.00 |
| Atrophic | 26 (14.1%) | 22 (19%) | 4 (5.8%) | 0.001 |
* Between H. pylori-positive and H. pylori-negative groups.
The relationship between chronic inflammation and H. pylori density.
| Chronic Inflammation 1 (n = 116) | ||||
|---|---|---|---|---|
| Mild | Moderate | Severe | ||
|
| 0.002 | |||
| Mild | 5 (55.5%) | 41 (54.7%) | 9 (28.1%) | |
| Moderate | 1 (11.1%) | 25 (33.3%) | 17 (53.1%) | |
| Severe | 3 (33.4%) | 9 (12.0%) | 6 (18.8%) | |
1 Shows the intensity of lymphocytes and plasma cells in lamina propria according to the Sydney System. 2 Refers to the density of H. pylori in gastric mucosa.
Eradication scheme and therapy compliance in H. pylori-positive patients.
| Treatment | |
| PPI + AMX + CLR * | 49 (42.2%) |
| PPI + AMX + MTZ | 62 (53.4%) |
| PPI + AMC + MTZ | 5 (4.3%) |
| Duration of treatment | |
| 14 days | 116 (100.0%) |
| Discontinuation of treatment | |
| Yes | 16 (13.8%) |
| No | 100 (86.2%) |
| Cause | |
| Treatment cost | 0 (0%) |
| Side effects | 5 (4.3%) |
| Misunderstanding of the treatment protocol | 11 (9.5%) |
| Side effects | |
| Yes | 34 (29.3%) |
| No | 82 (70.6%) |
| Persistence of symptoms | |
| Yes | 32 (27.5%) |
| No | 84 (72.4%) |
* PPI: proton pomp inhibitor; AMX: amoxicillin; CLR: clarithromycin; MTZ: metronidazole.